WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018067689) NOVEL HPV16 NON HLA-RESTRICTED T-CELL VACCINES, COMPOSITIONS AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/067689    International Application No.:    PCT/US2017/055119
Publication Date: 12.04.2018 International Filing Date: 04.10.2017
IPC:
A61K 38/00 (2006.01), A61K 39/12 (2006.01), A61K 39/00 (2006.01), C07K 14/00 (2006.01), A61K 9/127 (2006.01)
Applicants: PDS BIOTECHNOLOGY CORPORATION [US/US]; 675 US Highway 1 North Brunswick, NJ 08902 (US)
Inventors: BEDU-ADDO, Frank; (US).
CONN, Greg; (ES).
WARD, Martin; (US).
WOODWARD, Jerold; (US)
Agent: KULKARNI, Sima, Singadia; (US)
Priority Data:
62/404,458 05.10.2016 US
Title (EN) NOVEL HPV16 NON HLA-RESTRICTED T-CELL VACCINES, COMPOSITIONS AND METHODS OF USE THEREOF
(FR) NOUVEAUX VACCINS À LYMPHOCYTES T NON RESTREINTS À DES HLA DE HPV16, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Abstract: front page image
(EN)Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as cationic lipids.
(FR)L'invention concerne de nouvelles compositions immunogènes de papillomovirus humain et des procédés d'utilisation associés. Les compositions comprennent des combinaisons uniques de séquences peptidiques à plusieurs épitopes spécifiquement sélectionnées et conçues pour être efficacement traitées et présentées en réaction croisée à des lymphocytes T. Les peptides utilisés dans les compositions présentent des niveaux élevés de liaison avec des supertypes de HLA. Les compositions immunogènes sont largement applicables à de grandes proportions de populations cibles. Les compositions comprennent des adjuvants tels que des lipides cationiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)